Insider Spends US$387k Buying More Shares In Relmada Therapeutics
Insider Spends US$387k Buying More Shares In Relmada Therapeutics
Potential Relmada Therapeutics, Inc. (NASDAQ:RLMD) shareholders may wish to note that the CEO & Director, Sergio Traversa, recently bought US$387k worth of stock, paying US$3.87 for each share. That certainly has us anticipating the best, especially since they thusly increased their own holding by 69%, potentially signalling some real optimism.
潜在的Relmada Therapeutics, Inc.(纳斯达克股票代码:RLMD)股东不妨注意,首席执行官兼董事塞尔吉奥·特拉弗尔萨最近购买了价值38.7万美元的股票,每股支付了3.87美元。这无疑使我们对最好的情况充满期待,尤其是因为他们因此将自己的持股量增加了69%,这可能预示着一些真正的乐观情绪。
The Last 12 Months Of Insider Transactions At Relmada Therapeutics
Relmada Therapeutics 过去 12 个月的内幕交易
Notably, that recent purchase by Sergio Traversa is the biggest insider purchase of Relmada Therapeutics shares that we've seen in the last year. That means that an insider was happy to buy shares at above the current price of US$3.93. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.
值得注意的是,塞尔吉奥·特拉弗尔萨最近的收购是我们去年对Relmada Therapeutics股票的最大一次内幕收购。这意味着内部人士乐于以高于当前3.93美元的价格购买股票。从那以后,他们的观点可能发生了变化,但至少这表明他们当时感到乐观。对我们来说,考虑内部人士为股票支付的价格非常重要。总的来说,当内部人士以高于当前的价格购买股票时,它会引起我们的注意,因为这表明他们认为即使价格更高,也值得买入。
While Relmada Therapeutics insiders bought shares during the last year, they didn't sell. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
尽管Relmada Therapeutics内部人士在去年购买了股票,但他们没有卖出。下图显示了去年的内幕交易(公司和个人)。如果你点击图表,你可以看到所有的个人交易,包括股价、个人和日期!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240201/0-4d56e571872edaa59b9caf8ec1afd12d-0-72449a9cde60d7866e8c624f79f3a62a.png/big)
Relmada Therapeutics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Relmada Therapeutics并不是内部人士唯一买入的股票。对于那些喜欢寻找获利投资的人来说,这份最近有内幕收购的成长型公司的免费清单可能就是入场券。
Insider Ownership
内部所有权
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Insiders own 8.6% of Relmada Therapeutics shares, worth about US$10m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
查看公司的内部持股总量可以帮助你了解他们是否与普通股股东保持一致。我们通常希望看到相当高的内部所有权水平。业内人士拥有Relmada Therapeutics8.6%的股份,价值约1000万美元。当然,我们在其他地方看到了更高的内部所有权水平,但这些持股足以表明内部人士与其他股东之间的一致性。
So What Do The Relmada Therapeutics Insider Transactions Indicate?
那么,Relmada Therapeutics的内幕交易表明了什么呢?
It is good to see recent purchasing. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. Given that insiders also own a fair bit of Relmada Therapeutics we think they are probably pretty confident of a bright future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. For example, Relmada Therapeutics has 3 warning signs (and 1 which is concerning) we think you should know about.
很高兴看到最近的购买。长期的内幕交易也给了我们信心。但是,我们对公司亏损的事实有不同的看法。鉴于内部人士还拥有Relmada Therapeutics的相当一部分股份,我们认为他们可能对光明的未来充满信心。因此,这些内幕交易可以帮助我们建立有关股票的论点,但也值得了解这家公司面临的风险。例如,Relmada Therapeutics有3个警告信号(其中一个令人担忧),我们认为你应该知道。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,来看看这份有趣的公司的免费清单吧。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。